What is Marchex, Inc.'s earnings per share (EPS)?

Marchex, Inc. (MCHX) reported diluted earnings per share of -$0.12 for fiscal year 2025. This represents a -9.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Marchex, Inc. (MCHX) Financials

MCHX

FY2025 annual

Revenue $45.4M -5.6% YoY

Net Income -$5.2M -5.8% YoY

EPS (Diluted) -$0.12 -9.1% YoY

Free Cash Flow -$1.4M +2.8% YoY

Market Cap $54.5M as of Oct 13, 2026

Price / Sales 1.2x on $44.0M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 1.9x on $29.0M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MCHX SEC filings page.

Marchex, Inc. (MCHX) reported $45.4M in revenue for fiscal year 2025, down 5.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MCHX FY2025 2026-10-03

Marchex remains loss-making, as 2024's cost improvement weakened when revenue declined and operating expenses again outpaced gross profit.

As revenue contracted 5.6% in FY2025, operating margin moved from -9.2% to -12.6%, showing that the prior year's improvement depended partly on scale and cost restraint rather than a permanently lower cost structure. Meanwhile, SG&A increased 5.5% while R&D declined 21.5%, indicating a shift in spending mix rather than broad-based operating efficiency.

The company retains high gross profitability at 63.4% in FY2025, but that spread does not cover overhead: SG&A was $10.8M and R&D was $9.7M. The operating problem is therefore less about the direct cost of delivering revenue and more about the expense base required before gross profit becomes operating earnings.

Cash conversion is less negative than reported earnings: FY2025 operating cash flow was -$1.4M versus a net loss of $5.2M. Free cash flow was nearly the same because capital expenditures were only $36K, while a 2.4x current ratio, 0.3x debt-to-equity ratio, and reported liquidity comparison of 84.7 months point to limited balance-sheet leverage rather than debt-funded losses.

Financial Health Signals

Financial Health Score 50/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Marchex, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Marchex, Inc. held $9.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $1.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Marchex, Inc. scores 74/100 among other emerging companies.

Dilution

Not available for Marchex, Inc., and counted as zero in the overall score.

R&D Intensity

Marchex, Inc. spent $9.7M on research and development in fiscal year 2025, which was 19.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Marchex, Inc. scores 50/100 among other emerging companies.

Revenue Progress

Marchex, Inc. reported revenue of $45.4M in fiscal year 2025, against $48.1M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Marchex, Inc. scores 38/100 among other emerging companies.

Burn Trend

Marchex, Inc.'s operations used $1.4M of cash in fiscal year 2025, against $1.1M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Marchex, Inc. scores 79/100 among other emerging companies.

Balance Sheet

Marchex, Inc.'s cash, cash equivalents and investments came to $9.9M at the end of fiscal year 2025, against $9.6M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Marchex, Inc. scores 59/100 among other emerging companies.

Altman Z-Score Distress

-7.28

Marchex, Inc. scores -7.28, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($54.5M) relative to total liabilities ($9.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

Marchex, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Marchex, Inc. reported a net loss of $5.2M while operations used $1.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$11.0M

YoY-5.6%

QoQ+3.6%

5Y CAGR-4.7%

Marchex, Inc. generated $11.0M in revenue in Q2 2026. This represents a decrease of 5.6% from the same quarter a year earlier. Against the prior quarter it is up 3.6%.

EBITDA

-$93K

YoY+53.7%

QoQ+91.0%

Marchex, Inc.'s EBITDA was -$93K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 53.7% from the same quarter a year earlier. Against the prior quarter it is up 91.0%.

Net Income

-$408K

YoY-580.0%

QoQ+76.3%

Marchex, Inc. reported -$408K in net income in Q2 2026. This represents a decrease of 580.0% from the same quarter a year earlier. Against the prior quarter it is up 76.3%.

EPS (Diluted)

-$0.01

QoQ+75.0%

Marchex, Inc. earned -$0.01 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 75.0%.

Cash & Balance Sheet

Cash & Debt

$8.2M

YoY-22.3%

QoQ-9.6%

5Y CAGR-21.8%

10Y CAGR-22.6%

Marchex, Inc. held $8.2M in cash as of Q2 2026; long-term debt is not reported for that period.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Shares Outstanding

Not reported for Q2 2026.

Margins & Returns

Gross Margin

61.0%

YoY-4.2pp

QoQ-0.2pp

5Y change0.0pp

Marchex, Inc.'s gross margin was 61.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.

Operating Margin

-3.1%

YoY+1.5pp

QoQ+9.6pp

5Y change+17.3pp

Marchex, Inc.'s operating margin was -3.1% in Q2 2026, reflecting core business profitability. This is up 1.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 9.6 percentage points.

Net Margin

-3.7%

YoY-4.4pp

QoQ+12.5pp

5Y change-1.3pp

Marchex, Inc.'s net profit margin was -3.7% in Q2 2026, showing the share of revenue converted to profit. This is down 4.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.5 percentage points.

Return on Equity

-1.4%

YoY-1.7pp

QoQ+4.6pp

5Y change-0.7pp

Marchex, Inc.'s ROE was -1.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 1.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.6 percentage points.

Capital Allocation

R&D Spending

$2.0M

YoY-20.4%

QoQ-17.3%

5Y CAGR-16.1%

Marchex, Inc. invested $2.0M in research and development in Q2 2026. This represents a decrease of 20.4% from the same quarter a year earlier. Against the prior quarter it is down 17.3%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

MCHX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MCHX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$44.0M	$45.4M-5.6%	$48.1M-3.6%	$49.9M-4.3%	$52.2M-2.4%	$53.5M+4.4%	$51.2M-6.0%	$54.5M-36.1%	$85.3M-5.6%	$90.3M-30.3%	$129.5M-9.4%	$143.0M-17.6%	$173.6M+17.4%	$147.8M+11.3%	$132.8M-4.3%	$138.7M
Cost of Revenue	$16.8M	$16.6M-3.2%	$17.2M-16.6%	$20.6M+0.6%	$20.5M-5.7%	$21.7M+3.9%	$20.9M+16.0%	$18.0M-62.3%	$47.8M-3.1%	$49.3M	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$27.2M	$28.8M-7.0%	$30.9M+5.5%	$29.3M-7.5%	$31.7M-0.2%	$31.8M+4.8%	$30.3M-16.9%	$36.5M-2.6%	$37.4M-8.6%	$41.0M	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9.0M	$9.7M-21.5%	$12.4M-19.2%	$15.4M+7.0%	$14.4M-10.9%	$16.1M-23.3%	$21.0M+17.5%	$17.9M+15.9%	$15.4M-14.8%	$18.1M-36.4%	$28.4M-8.4%	$31.1M+5.1%	$29.6M+8.2%	$27.3M+17.8%	$23.2M+2.6%	$22.6M
SG&A Expenses	$10.0M	$10.8M+5.5%	$10.2M+0.4%	$10.2M+4.3%	$9.8M+5.3%	$9.3M-27.4%	$12.8M-1.7%	$13.0M+19.7%	$10.9M-19.8%	$13.6M-37.6%	$21.8M+17.5%	$18.5M-11.5%	$20.9M+8.1%	$19.4M-15.2%	$22.8M+0.8%	$22.7M
Operating Income	-$5.0M	-$5.7M-28.7%	-$4.4M+53.9%	-$9.6M-18.3%	-$8.1M+30.9%	-$11.8M+73.2%	-$44.1M-215.6%	-$14.0M-259.1%	-$3.9M+38.9%	-$6.4M+92.4%	-$83.9M-16447.7%	-$507K-128.4%	-$222K+89.4%	-$2.1M+87.8%	-$17.2M-401.2%	$5.7M
EBITDA	N/A	-$4.4M-43.5%	-$3.0M+61.2%	-$7.9M-20.0%	-$6.5M+38.2%	-$10.6M+75.0%	-$42.5M-240.8%	-$12.5M-421.8%	-$2.4M+32.9%	-$3.6M+95.6%	-$80.7M-2709.0%	$3.1M-2.7%	$3.2M+144.8%	$1.3M+109.2%	-$14.0M-264.7%	$8.5M
Interest Expense	N/A	N/A	N/A	$282K	N/A	$37K+23.3%	$30K	N/A	N/A	N/A	$109K+43.4%	$76K0.0%	$76K0.0%	$76K-82.6%	$438K-27.5%	$604K
Income Tax	$276K	$79K-79.2%	$380K+304.3%	$94K-48.9%	$184K-20.7%	$232K+112.1%	-$1.9M+44.9%	-$3.5M-2128.2%	-$156K-471.4%	$42K-22.2%	$54K+100.0%	$27K-99.9%	$22.5M+97765.2%	$23K-99.9%	$16.6M+559.7%	$2.5M
Net Income	-$5.5M	-$5.2M-5.8%	-$4.9M+50.1%	-$9.9M-20.2%	-$8.2M-87.8%	-$4.4M+88.6%	-$38.4M-851.2%	-$4.0M-50.9%	-$2.7M+56.0%	-$6.1M+92.8%	-$84.1M-414.6%	$26.7M+240.0%	-$19.1M-1150.6%	$1.8M+105.2%	-$35.2M-1289.5%	$3.0M
EPS (Basic)	N/A	-$0.12-9.1%	-$0.11+52.2%	-$0.23-21.1%	-$0.19-90.0%	-$0.10	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.12	-$0.12-9.1%	-$0.11+52.2%	-$0.23-21.1%	-$0.19-90.0%	-$0.10	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$11.0M-5.6%	$10.6M-6.9%	$10.8M-9.0%	$11.5M-8.3%	$11.7M-3.5%	$11.4M-1.5%	$11.9M-3.8%	$12.6M-1.8%
Cost of Revenue	$4.3M+5.7%	$4.1M-1.6%	$4.2M-5.0%	$4.2M-0.2%	$4.1M-2.3%	$4.2M-5.1%	$4.4M-6.4%	$4.2M-16.5%
Gross Profit	$6.7M-11.6%	$6.5M-9.9%	$6.7M-11.3%	$7.3M-12.4%	$7.6M-4.1%	$7.2M+0.8%	$7.5M-2.2%	$8.3M+7.9%
R&D Expenses	$2.0M-20.4%	$2.4M-9.9%	$2.2M-22.4%	$2.4M-23.7%	$2.5M-22.4%	$2.7M-17.7%	$2.8M-9.9%	$3.1M-21.2%
SG&A Expenses	$2.7M+8.1%	$2.1M-33.1%	$2.3M-17.7%	$2.9M+9.7%	$2.5M-2.8%	$3.1M+37.4%	$2.8M-1.4%	$2.7M+18.9%
Operating Income	-$346K+35.4%	-$1.4M+27.8%	-$2.4M-49.7%	-$941K-14.1%	-$536K+25.8%	-$1.9M-42.5%	-$1.6M-41.6%	-$825K+37.5%
EBITDA	-$93K+53.7%	-$1.0M+31.1%	-$2.1M-68.5%	-$629K-51.9%	-$201K+51.3%	-$1.5M-48.7%	-$1.2M-38.3%	-$414K+19.9%
Income Tax	$111K+2120.0%	$199K+84.3%	-$61K-120.8%	$27K+8.0%	$5K+66.7%	$108K+83.1%	$293K+614.6%	$25K+177.8%
Net Income	-$408K-580.0%	-$1.7M+13.0%	-$2.3M-21.4%	-$1.0M-22.7%	$85K+111.2%	-$2.0M-36.7%	-$1.9M-67.1%	-$831K+46.3%
EPS (Basic)	-$0.01	-$0.04+20.0%	-$0.05-25.0%	-$0.020.0%	$0.00+100.0%	-$0.05-66.7%	-$0.04-100.0%	-$0.02+50.0%
EPS (Diluted)	-$0.01	-$0.04+20.0%	-$0.05-25.0%	-$0.020.0%	$0.00+100.0%	-$0.05-66.7%	-$0.04-100.0%	-$0.02+50.0%

Not reported in any period shown, so not listed: Interest Expense, Diluted Shares (Avg).

MCHX Balance Sheet

MCHX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$39.7M-8.1%	$43.2M-9.0%	$47.5M-16.4%	$56.8M-13.7%	$65.8M-14.4%	$76.9M-38.2%	$124.5M+10.1%	$113.1M-8.7%	$123.8M-3.5%	$128.3M-37.4%	$205.0M+13.5%	$180.7M+11.4%	$162.1M+8.7%	$149.1M-32.2%	$220.1M
Current Assets	$19.0M-14.5%	$22.3M-6.4%	$23.8M-22.9%	$30.9M-17.7%	$37.5M-11.4%	$42.3M-32.2%	$62.4M-2.6%	$64.1M-47.1%	$121.1M-2.7%	$124.5M-8.2%	$135.7M+24.2%	$109.2M+68.1%	$65.0M+42.2%	$45.7M-38.8%	$74.6M
Cash & Equivalents	$9.9M-22.1%	$12.8M-12.6%	$14.6M-28.7%	$20.5M-24.4%	$27.1M-20.0%	$33.9M-18.9%	$41.7M-7.7%	$45.2M-56.6%	$104.2M+0.2%	$104.0M-4.8%	$109.2M+36.4%	$80.0M+158.9%	$30.9M+94.0%	$15.9M-57.5%	$37.4M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$6.7M-5.7%	$7.1M-4.4%	$7.4M-11.9%	$8.4M+4.7%	$8.0M+26.7%	$6.3M-15.9%	$7.5M-53.5%	$16.2M+9.0%	$14.9M-21.5%	$18.9M-23.1%	$24.6M-5.1%	$25.9M-13.5%	$30.0M+15.5%	$26.0M-15.2%	$30.6M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$17.6M0.0%	$17.6M0.0%	$17.6M0.0%	$17.6M0.0%	$17.6M0.0%	$17.6M-45.7%	$32.3M+32.3%	$24.4M	$0	$0-100.0%	$63.3M-3.6%	$65.7M0.0%	$65.7M-0.2%	$65.8M-20.4%	$82.6M
Total Liabilities	$9.6M-9.2%	$10.6M-9.0%	$11.6M-8.5%	$12.7M-11.5%	$14.3M-40.9%	$24.2M-1.7%	$24.7M+36.7%	$18.0M-46.7%	$33.8M+125.5%	$15.0M-14.4%	$17.5M-28.5%	$24.5M-10.5%	$27.4M+4.5%	$26.2M-57.1%	$61.0M
Current Liabilities	$8.1M-13.0%	$9.3M-4.7%	$9.7M-19.4%	$12.1M-4.8%	$12.7M-39.5%	$21.0M+19.4%	$17.5M+18.8%	$14.8M-54.9%	$32.7M+120.2%	$14.9M-11.8%	$16.9M-27.9%	$23.4M-7.5%	$25.3M+5.4%	$24.0M-59.0%	$58.5M
Non-Current Liabilities	$1.5M+17.7%	$1.3M-31.1%	$1.9M+205.3%	$618K-62.6%	$1.7M-49.8%	$3.3M-53.8%	$7.1M+118.1%	$3.3M+199.4%	$1.1M+713.4%	$134K-79.8%	$662K-40.8%	$1.1M-46.6%	$2.1M-5.5%	$2.2M-14.1%	$2.6M
Total Equity	$30.1M-7.8%	$32.6M-9.0%	$35.9M-18.7%	$44.1M-14.3%	$51.5M-2.3%	$52.7M-47.2%	$99.8M+5.1%	$95.0M+5.6%	$90.0M-20.5%	$113.3M-39.6%	$187.5M+20.1%	$156.2M+15.9%	$134.8M+9.6%	$122.9M-22.7%	$159.0M
Retained Earnings	-$331.4M-1.6%	-$326.2M-1.5%	-$321.2M-3.2%	-$311.3M-2.7%	-$303.1M-1.5%	-$298.7M-14.8%	-$260.2M-1.6%	-$256.2M-1.0%	-$253.7M-2.5%	-$247.6M-51.4%	-$163.5M+14.0%	-$190.2M-11.2%	-$171.1M+1.1%	-$173.0M-25.5%	-$137.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$37.6M-10.4%	$38.5M-5.1%	$39.7M-8.1%	$41.1M-6.6%	$42.0M-7.7%	$40.6M-10.9%	$43.2M-9.0%	$44.1M-10.2%
Current Assets	$17.4M-17.3%	$18.1M-8.9%	$19.0M-14.5%	$20.4M-6.4%	$21.1M-6.2%	$19.9M-11.3%	$22.3M-6.4%	$21.8M-9.0%
Cash & Equivalents	$8.2M-22.3%	$9.0M-10.0%	$9.9M-22.1%	$10.3M-14.5%	$10.5M-12.4%	$10.0M-16.7%	$12.8M-12.6%	$12.1M-11.9%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$7.1M-6.6%	$6.8M-10.0%	$6.7M-5.7%	$7.4M-4.7%	$7.6M-1.0%	$7.6M-6.9%	$7.1M-4.4%	$7.8M-4.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$17.6M0.0%	$17.6M0.0%	$17.6M0.0%	$17.6M0.0%	$17.6M0.0%	$17.6M0.0%	$17.6M0.0%	$17.6M0.0%
Total Liabilities	$8.6M-13.5%	$9.7M+4.7%	$9.6M-9.2%	$9.2M-7.6%	$9.9M-9.4%	$9.3M-13.7%	$10.6M-9.0%	$10.0M-15.6%
Current Liabilities	$7.6M-12.9%	$8.2M+2.8%	$8.1M-13.0%	$8.1M-6.9%	$8.7M-7.8%	$8.0M-11.7%	$9.3M-4.7%	$8.7M-11.7%
Non-Current Liabilities	$994K-17.8%	$1.5M+16.5%	$1.5M+17.7%	$1.1M-12.2%	$1.2M-19.5%	$1.3M-24.4%	$1.3M-31.1%	$1.3M-35.0%
Total Equity	$29.0M-9.4%	$28.9M-8.0%	$30.1M-7.8%	$31.9M-6.4%	$32.0M-7.2%	$31.4M-10.0%	$32.6M-9.0%	$34.1M-8.5%
Retained Earnings	-$333.5M-1.7%	-$333.1M-1.5%	-$331.4M-1.6%	-$329.1M-1.5%	-$328.1M-1.4%	-$328.2M-1.7%	-$326.2M-1.5%	-$324.3M-1.3%

Not reported in any period shown, so not listed: Inventory, Long-Term Debt.

MCHX Cash Flow Statement

MCHX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$752K	-$1.4M-27.5%	-$1.1M+74.9%	-$4.4M-91.8%	-$2.3M+63.9%	-$6.3M-88.0%	-$3.4M-166.2%	$5.1M+0.9%	$5.1M+198.5%	$1.7M+146.1%	-$3.7M-128.8%	$12.8M-43.1%	$22.4M+64.9%	$13.6M-31.7%	$19.9M+18.6%	$16.8M
Depreciation & Amortization	N/A	$1.4M-3.5%	$1.4M-21.5%	$1.8M+11.4%	$1.6M+33.3%	$1.2M-25.0%	$1.6M+6.7%	$1.5M0.0%	$1.5M-46.4%	$2.8M-12.5%	$3.2M-11.1%	$3.6M+5.9%	$3.4M0.0%	$3.4M+6.3%	$3.2M+14.3%	$2.8M
Stock-Based Compensation	N/A	$2.4M+39.8%	$1.7M-28.7%	$2.4M-9.6%	$2.6M-1.0%	$2.7M-30.3%	$3.8M+21.8%	$3.1M+3.5%	$3.0M-33.9%	$4.6M-54.9%	$10.2M+1.6%	$10.0M-15.8%	$11.9M+28.5%	$9.3M-41.0%	$15.7M+3.7%	$15.1M
Capital Expenditures	N/A	$36K-90.6%	$382K-72.3%	$1.4M-51.9%	$2.9M+112.1%	$1.4M-0.1%	$1.4M-16.6%	$1.6M-1.7%	$1.7M+5.7%	$1.6M+58.4%	$986K-76.0%	$4.1M+25.8%	$3.3M+7.4%	$3.0M+5.6%	$2.9M-27.5%	$4.0M
Free Cash Flow	N/A	-$1.4M+2.8%	-$1.5M+74.3%	-$5.8M-11.9%	-$5.2M+33.0%	-$7.7M-62.8%	-$4.7M-236.2%	$3.5M+2.1%	$3.4M+2515.4%	$130K+102.8%	-$4.7M-153.8%	$8.6M-54.9%	$19.2M+81.5%	$10.6M-38.0%	$17.0M+32.9%	$12.8M
Investing Cash Flow	-$1.5M	-$1.3M-207.7%	-$429K+67.3%	-$1.3M+54.2%	-$2.9M-201.3%	-$951K-196.9%	$981K+110.1%	-$9.7M+73.5%	-$36.6M-2218.5%	-$1.6M-28.8%	-$1.2M-105.6%	$21.8M+786.7%	-$3.2M-293.0%	$1.6M-50.4%	$3.3M+131.9%	-$10.4M
Financing Cash Flow	-$124K	-$97K+68.4%	-$307K-91.9%	-$160K+89.0%	-$1.5M-375.6%	$528K+109.6%	-$5.5M-391.1%	$1.9M+106.9%	-$27.4M-22058.4%	$125K+140.1%	-$312K+94.3%	-$5.5M-118.2%	$29.9M+11547.9%	-$261K+99.4%	-$44.7M-612.9%	-$6.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$21.9M	N/A	N/A	$1.7M-49.4%	$3.3M	N/A	$9.4M+219.1%	$2.9M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	$10.9M	N/A	$5.7M	N/A	$365K-90.5%	$3.8M+53.7%	$2.5M+1989.1%	$119K-92.8%	$1.7M-73.2%	$6.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$649K-180.8%	-$514K+80.4%	$121K-86.2%	$290K-24.1%	$803K+586.3%	-$2.6M-5.8%	$875K-50.1%	$382K+201.1%
Depreciation & Amortization	$253K-24.5%	$322K-14.8%	$325K-12.2%	$312K-24.1%	$335K+8.4%	$378K+22.3%	$370K+30.7%	$411K-48.8%
Stock-Based Compensation	$531K-4.5%	$489K+7.5%	N/A	$920K+123.8%	$556K+27.2%	$455K+5.1%	N/A	$411K+1.0%
Capital Expenditures	N/A	N/A	$5K-95.8%	$0-100.0%	N/A	N/A	$118K-86.2%	$183K+9050.0%
Free Cash Flow	N/A	N/A	$116K-84.7%	$290K+45.7%	N/A	N/A	$757K-16.0%	$199K+152.4%
Investing Cash Flow	-$275K-8.7%	-$411K-42.2%	-$428K-159.4%	-$350K-91.3%	-$253K-228.6%	-$289K-7125.0%	-$165K+80.7%	-$183K-385.9%
Financing Cash Flow	$56K+170.9%	$2K-98.8%	-$72K-242.9%	-$110K-12.2%	-$79K+16.8%	$164K+276.3%	-$21K-110.0%	-$98K-7.7%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

MCHX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MCHX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	63.4%-0.9pp	64.3%+5.6pp	58.8%-2.0pp	60.8%+1.3pp	59.4%+0.2pp	59.2%-7.7pp	67.0%+23.0pp	43.9%-1.4pp	45.4%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-12.6%-3.4pp	-9.2%+10.1pp	-19.3%-3.7pp	-15.6%+6.4pp	-22.1%+64.0pp	-86.0%-60.4pp	-25.6%-21.1pp	-4.6%+2.5pp	-7.0%+57.7pp	-64.8%-64.4pp	-0.4%-0.2pp	-0.1%+1.3pp	-1.4%+11.6pp	-13.0%-17.1pp	4.1%
Net Margin	-11.5%-1.2pp	-10.3%+9.6pp	-19.9%-4.1pp	-15.8%-7.6pp	-8.2%+66.9pp	-75.1%-67.6pp	-7.4%-4.3pp	-3.1%+3.6pp	-6.7%+58.1pp	-64.9%-83.6pp	18.7%+29.7pp	-11.0%-12.2pp	1.2%+27.7pp	-26.5%-28.6pp	2.1%
Return on Equity	-17.4%-2.2pp	-15.2%+12.5pp	-27.6%-8.9pp	-18.7%-10.2pp	-8.5%+64.5pp	-73.0%-68.9pp	-4.0%-1.2pp	-2.8%+3.9pp	-6.8%+67.5pp	-74.2%-88.5pp	14.2%+26.5pp	-12.2%-13.6pp	1.4%+30.0pp	-28.6%-30.5pp	1.9%
Return on Assets	-13.2%-1.7pp	-11.5%+9.4pp	-20.9%-6.3pp	-14.5%-7.8pp	-6.7%+43.3pp	-50.0%-46.7pp	-3.3%-0.9pp	-2.4%+2.6pp	-4.9%+60.6pp	-65.5%-78.6pp	13.0%+23.6pp	-10.6%-11.7pp	1.1%+24.7pp	-23.6%-24.9pp	1.3%
Current Ratio	2.360.0x	2.400.0x	2.45-0.1x	2.56-0.4x	2.96+0.9x	2.02-1.5x	3.56-0.8x	4.34+0.6x	3.70-4.7x	8.37+0.3x	8.05+3.4x	4.67+2.1x	2.57+0.7x	1.90+0.6x	1.28
Debt-to-Equity	0.320.0x	0.320.0x	0.320.0x	0.290.0x	0.28-0.2x	0.46+0.2x	0.25+0.1x	0.19-0.2x	0.38+0.2x	0.130.0x	0.09-0.1x	0.160.0x	0.200.0x	0.21-0.2x	0.38
Asset Turnover	1.140.0x	1.11+0.1x	1.05+0.1x	0.92+0.1x	0.81+0.1x	0.67+0.2x	0.44-0.3x	0.750.0x	0.73-0.3x	1.01+0.3x	0.70-0.3x	0.960.0x	0.910.0x	0.89+0.3x	0.63
FCF Margin	-3.2%-0.1pp	-3.1%+8.5pp	-11.6%-1.7pp	-9.9%+4.5pp	-14.4%-5.2pp	-9.2%-15.6pp	6.4%+2.4pp	4.0%+3.9pp	0.1%+3.7pp	-3.6%-9.6pp	6.0%-5.0pp	11.0%+3.9pp	7.1%-5.7pp	12.8%+3.6pp	9.2%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	61.0%-4.2pp	61.2%-2.1pp	61.6%-1.6pp	63.4%-3.0pp	65.2%-0.4pp	63.3%+1.4pp	63.2%+1.0pp	66.3%+5.9pp
Operating Margin	-3.1%+1.5pp	-12.7%+3.7pp	-21.9%-8.6pp	-8.2%-1.6pp	-4.6%+1.4pp	-16.4%-5.1pp	-13.3%-4.3pp	-6.6%+3.8pp
Net Margin	-3.7%-4.4pp	-16.2%+1.1pp	-21.4%-5.3pp	-8.9%-2.2pp	0.7%+7.0pp	-17.4%-4.9pp	-16.0%-6.8pp	-6.6%+5.5pp
Return on Equity	-1.4%-1.7pp	-6.0%+0.3pp	-7.7%-1.9pp	-3.2%-0.7pp	0.3%+2.5pp	-6.3%-2.2pp	-5.9%-2.7pp	-2.4%+1.7pp
Return on Assets	-1.1%-1.3pp	-4.5%+0.4pp	-5.8%-1.4pp	-2.5%-0.6pp	0.2%+1.9pp	-4.9%-1.7pp	-4.4%-2.0pp	-1.9%+1.3pp
Current Ratio	2.29-0.1x	2.22-0.3x	2.360.0x	2.530.0x	2.420.0x	2.500.0x	2.400.0x	2.52+0.1x
Debt-to-Equity	0.300.0x	0.340.0x	0.320.0x	0.290.0x	0.310.0x	0.300.0x	0.320.0x	0.290.0x
Asset Turnover	0.290.0x	0.280.0x	0.270.0x	0.280.0x	0.280.0x	0.280.0x	0.280.0x	0.280.0x
FCF Margin	N/A	N/A	1.1%-5.3pp	2.5%+0.9pp	N/A	N/A	6.3%-0.9pp	1.6%+4.6pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Marchex, Inc. MCHX	FY2025	$45.4M	-$5.2M	-11.5%	$54.5M	50/100
Thumzup Media Corporation TZUP	FY2025	$7.0M	-$8.5M	N/A	$75.3M	47/100
TOWNSQUARE MEDIA, INC. TSQ	FY2025	$427.4M	-$11.5M	-2.7%	$75.8M	31/100
VS Media Holdings Limited VSME	FY2025	$7.5M	-$8.6M	N/A	$3.6M	33/100
Cardlytics, Inc. CDLX	FY2025	$233.3M	-$104.0M	-44.6%	$13.2M	24/100
Entravision Communication EVC	FY2025	$447.6M	-$79.0M	-17.6%	$600.8M	40/100

Where Marchex, Inc. Ranks

Frequently Asked Questions

What is Marchex, Inc.'s annual revenue?

Marchex, Inc. (MCHX) reported $45.4M in total revenue for fiscal year 2025. This represents a -5.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Marchex, Inc.'s revenue growing?

Marchex, Inc. (MCHX) revenue declined by 5.6% year-over-year, from $48.1M to $45.4M in fiscal year 2025.

Is Marchex, Inc. profitable?

No, Marchex, Inc. (MCHX) reported a net income of -$5.2M in fiscal year 2025, with a net profit margin of -11.5%.

What is Marchex, Inc.'s EBITDA?

Marchex, Inc. (MCHX) had EBITDA of -$4.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Marchex, Inc.'s gross margin?

Marchex, Inc. (MCHX) had a gross margin of 63.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Marchex, Inc.'s operating margin?

Marchex, Inc. (MCHX) had an operating margin of -12.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Marchex, Inc.'s net profit margin?

Marchex, Inc. (MCHX) had a net profit margin of -11.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Marchex, Inc.'s return on equity (ROE)?

Marchex, Inc. (MCHX) has a return on equity of -17.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Marchex, Inc.'s free cash flow?

Marchex, Inc. (MCHX) recorded an outflow of $1.4M in free cash flow during fiscal year 2025. This represents a 2.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Marchex, Inc.'s operating cash flow?

Marchex, Inc. (MCHX) recorded an outflow of $1.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Marchex, Inc.'s total assets?

Marchex, Inc. (MCHX) had $39.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Marchex, Inc.'s capital expenditures?

Marchex, Inc. (MCHX) invested $36K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Marchex, Inc. spend on research and development?

Marchex, Inc. (MCHX) invested $9.7M in research and development during fiscal year 2025.

What is Marchex, Inc.'s current ratio?

Marchex, Inc. (MCHX) had a current ratio of 2.36 as of fiscal year 2025, which is generally considered healthy.

What is Marchex, Inc.'s debt-to-equity ratio?

Marchex, Inc. (MCHX) had a debt-to-equity ratio of 0.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Marchex, Inc.'s return on assets (ROA)?

Marchex, Inc. (MCHX) had a return on assets of -13.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Marchex, Inc.'s P/E ratio?

Marchex, Inc. (MCHX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $54.5M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Marchex, Inc.'s price-to-sales ratio?

Marchex, Inc. (MCHX) trades at 1.2x sales, its market capitalization divided by revenue of $44.0M revenue, trailing 12 months to June 30, 2026. The market capitalization is $54.5M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Marchex, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Marchex, Inc. (MCHX) held $9.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $1.4M over that year. Dividing the one by the other, the reported balance equals about 85 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Marchex, Inc.'s Altman Z-Score?

Marchex, Inc. (MCHX) has an Altman Z-Score of -7.28, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Marchex, Inc.'s Piotroski F-Score?

Marchex, Inc. (MCHX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Marchex, Inc.'s earnings high quality?

Marchex, Inc. (MCHX) reported a net loss of $5.2M while operations used $1.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Marchex, Inc.?

Marchex, Inc. (MCHX) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.